Alpelisib

In this article, we will discuss Alpelisib (Dosage Overview). So, let’s get started.

Alpelisib is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men,
with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.

Dosage

Patient Selection

Select patients for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer with Alpelisib, based on the presence of one or more PIK3CA mutations in tumor tissue or plasma specimens. If no mutation is detected in a plasma specimen, test tumor tissue.

Dosage and Administration

The recommended dose of Alpelisib is 300 mg (two 150 mg film-coated tablets) taken orally, once daily, with food.

Continue treatment until disease progression or unacceptable toxicity occurs.

If a dose of Alpelisib is missed, it can be taken with food within 9 hours after the time it is usually taken. After more than 9 hours, skip the dose for that day. The next day, take Alpelisib at the usual time.

When given with Alpelisib, the recommended dose of fulvestrant is 500 mg administered on Days 1, 15, and 29, and once monthly thereafter.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.